

EMA/607137/2019

European Medicines Agency decision P/0400/2019

of 4 December 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721) (EMEA-002479-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0400/2019

of 4 December 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721) (EMA-002479-PIP01-18) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Omeros London Limited on 22 November 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721), solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721), solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721), solution for injection / infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Omeros London Limited, 2nd Floor, Berkeley Square House, Berkeley Square, W1J 6BD – London, United Kingdom.

EMA/PDCO/462788/2019 Corr
Amsterdam, 18 October 2019

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002479-PIP01-18

Scope of the application

Active substance(s):

Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (OMS721)

Condition(s):

Treatment in haematopoietic stem cell transplantation

Pharmaceutical form(s):

Solution for injection/infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Omeros London Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Omeros London Limited submitted for agreement to the European Medicines Agency on 22 November 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 3 January 2019.

Supplementary information was provided by the applicant on 10 July 2019. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment in haematopoietic stem cell transplantation

The waiver applies to:

- the paediatric population from birth to less than 28 days;
- solution for injection/infusion, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2. Paediatric investigation plan

2.1. Condition

Treatment in haematopoietic stem cell transplantation

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients aged from 28 days to less than 18 years of age with haematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years old

2.1.3. Pharmaceutical form(s)

Solution for injection/infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	1	Study 1 Definitive juvenile mice toxicity study.
Clinical studies	1	Study 2 Open-label pharmacokinetic and pharmacodynamics study of OMS721 in paediatric subjects who received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease and are at high-risk of HSCT-TMA (OMS721-HCT-002).

Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	1	Study 3 Retrospective medical record review to collect data from paediatric patients with high-risk HSCT-TMA to build a control group for Study 2.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By October 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes